Johnson & Johnson Advances Cancer and Immunology Treatments With Major Biotech Deals
Johnson & Johnson expands its biotech pipeline with Firefly Bio acquisition and a strategic partnership with Sail Biomedicines.
Johnson & Johnson is buying smaller companies and teaming up with others to create new medicines for cancer and immune diseases. When a big company invests in new treatments like this, it shows they're working hard to grow and help patients—something to notice when you follow the company.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.